Evaluating DSLT as First Treatment for Adults Aged 30 and Older with Newly Diagnosed Primary Open Angle Glaucoma

What this Trial Is About

Researchers are investigating how the device-assisted procedure DSLT works as a first treatment option for patients newly diagnosed with primary open angle glaucoma POAG. This research focuses on patients who have not received any previous glaucoma treatments and aims to see if DSLT can reduce intraocular pressure IOP effectively, helping to manage the condition without the need for medications. The study is observational and sponsored by Barnet Dulaney Perkins Eye Centers. The intervention involves the use of DSLT, a device-based procedure designed for patients with mild to moderate POAG and IOP between 18 and 26 mmHg. The study specifically includes patients who have not had prior glaucoma treatment such as medication, laser therapy, or surgery. DSLT is being evaluated to determine if it allows patients to maintain good eye pressure control without starting medication. Participants will be monitored over 12 months to assess the success of IOP reduction through DSLT. Researchers will measure the change from pre-treatment baseline IOP and look for other improvements in the disease state. Throughout the study, patients will have assessments to track eye pressure and overall disease progress, helping to understand how well DSLT supports newly diagnosed POAG patients in controlling their glaucoma.

DSLT Performance in Treatment-naïve Patients With Newly Diagnosed Open Angle Glaucoma